MET ALTERATION

Clinical trials for MET ALTERATION explained in plain language.

Never miss a new study

Get alerted when new MET ALTERATION trials appear

Sign up with your email to follow new studies for MET ALTERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug cocktail aims to outsmart lung cancer resistance

Disease control Not yet recruiting

This study tests a new drug (ANS014004) combined with a standard targeted therapy (EGFR-TKI) in people with advanced EGFR-mutated non-small cell lung cancer. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing, especially when th…

Matched conditions: MET ALTERATION

Phase: PHASE1, PHASE2 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control

Last updated Apr 29, 2026 02:52 UTC

MET ALTERATION

Get alerted when new MET ALTERATION trials appear

New drug cocktail aims to outsmart lung cancer resistance